ID | 118258 |
タイトル別表記 | 血漿Heparin Cofactor II活性は2型糖尿病患者における非アルコール性脂肪性肝疾患肝線維化と逆相関する
Heparin Cofactor II and NAFLD in T2DM
|
著者 |
Uemoto, Ryoko
Tokushima University
Sekine, Akiko
Tokushima University
Mitsui, Yukari
Tokushima University
Masuda, Shiho
Tokushima University
乙田, 敏城
Tokushima University
Honda, Soichi
Minami Municipal National Insurance Hospital
Kondo, Akira
Kondo Naika Hospital
|
キーワード | ヘパリンコファクターII
プロテアーゼ活性化受容体
糖尿病
NAFLD
横断研究
Thrombin
Protease-activated receptors
Heparin cofactor II
T2DM
|
資料タイプ |
学位論文
|
抄録 | Aims: Thrombin exerts various pathophysiological functions by activating protease-activated receptors (PARs), and thrombin-induced activation of PARs promotes the development of non-alcoholic fatty liver disease (NAFLD). Since heparin cofactor II (HCII) specifically inactivates thrombin action, we hypothesized that plasma HCII activity correlates with the severity of NAFLD.
Methods: A cross-sectional study was conducted. Plasma HCII activity and noninvasive clinical markers of hepatic fibrosis including fibrosis-4 (FIB-4) index, NAFLD fibrosis score (NFS) and aspartate aminotransferase-to-platelet ratio index (APRI) were determined in 305 Japanese patients with type 2 diabetes mellitus (T2DM). The relationships between plasma HCII activity and the clinical markers were statistically evaluated. Results: Multiple regression analysis including confounding factors showed that plasma HCII activity independently contributed to decreases in FIB-4 index (p<0.001), NFS (p<0.001) and APRI (p=0.004). In addition, logistic regression analysis for the prevalence of advanced hepatic fibrosis defined by the cutoff points of the clinical scores showed that plasma HCII activity was the sole and common negative factor for prevalence of advanced hepatic fibrosis (FIB-4 index: p=0.002, NFS: p=0.026 and APRI: p=0.012). Conclusions: Plasma HCII activity was inversely associated with clinical hepatic fibrosis indices including FIB-4 index, NFS and APRI and with the prevalence of advanced hepatic fibrosis in patients with T2DM. The results suggest that HCII can serve as a novel biomarker for assessment of hepatic fibrosis of NAFLD in patients with T2DM. |
掲載誌名 |
Journal of Atherosclerosis and Thrombosis
|
ISSN | 18803873
13403478
|
出版者 | Japan Atherosclerosis Society
|
巻 | 30
|
号 | 8
|
開始ページ | 871
|
終了ページ | 883
|
発行日 | 2023-08-01
|
備考 | 内容要旨・審査要旨・論文本文の公開
本論文は,著者Tomoyo Haraの学位論文として提出され,学位審査・授与の対象となっている。 |
権利情報 | This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.( https://creativecommons.org/licenses/by-nc-sa/4.0/deed.ja )
|
EDB ID | |
出版社版DOI | |
出版社版URL | |
フルテキストファイル | |
言語 |
eng
|
著者版フラグ |
博士論文全文を含む
|
文科省報告番号 | 甲第3689号
|
学位記番号 | 甲医第1554号
|
学位授与年月日 | 2023-03-23
|
学位名 |
博士(医学)
|
学位授与機関 |
徳島大学
|
部局 |
医学系
病院
先端酵素学研究所
歯学系
|